Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)
This study has been completed.
First Posted: July 12, 2011
Last Update Posted: February 4, 2016
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )